Pharma’s post-pandemic launch performance problem: what’s the prognosis?
pharmaphorum
JUNE 29, 2022
COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. Sarah Rickwood has 30 years’ experience as a consultant to the pharmaceutical industry. The scope of the problem.
59 
Let's personalize your content